Discover investment opportunities in Top 100 Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 100 Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 100 Stocks Under $3 using our Smart AI Filter.
7 stocks found for "Top 100 Stocks Under $3"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.01 Risk measure | ±100.0% Price volatility | — Valuation | 0.00% Annual yield | |||
1.40 Risk measure | ±59.3% Price volatility | -45.5 Valuation | 0.00% Annual yield | |||
0.44 Risk measure | ±100.0% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
0.79 Risk measure | ±46.9% Price volatility | -62.2 Valuation | 0.00% Annual yield | |||
1.71 Risk measure | ±83.6% Price volatility | 46.2 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±71.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±88.4% Price volatility | -5.2 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What are the potential growth prospects for DNN in the uranium mining sector?
A: DNN, or Denison Mines Corp, operates in the uranium mining sector, which may benefit from increased demand for nuclear energy as a clean energy source. However, uranium prices are volatile, and regulatory changes could impact growth prospects. Analyzing industry trends and company-specific projects is crucial.
Q: How does ZSPC's market performance compare to its sector averages?
A: ZSPC operates in a niche market, and its performance should be compared against sector-specific indices and peer companies. Investors may consider revenue growth, profitability, and market trends to determine its competitiveness and alignment with sector movements.
Q: Is RVPH considered a high-risk investment due to its biotech involvement?
A: As a biotech company, RVPH may present high risk due to the inherent uncertainties in drug development, regulatory approvals, and market competition. Investors should weigh the company's pipeline, financial health, and industry environment when assessing risk.
Q: Do investors see OSTX as a strong contender in the technology sector?
A: OSTX might appeal to technology sector investors seeking innovation and growth potential. However, its competitiveness relies on its market positioning, technological advancements, and financial stability compared to larger tech firms.
Q: What dividend income prospects does WRN offer to investors?
A: WRN, involved in the mining sector, typically does not focus on dividends but rather on growth through exploration and development projects. Prospective investors should assess the potential for capital gains over dividend income.
Q: How might OKUR's consumer base affect its market volatility?
A: OKUR's market volatility can be influenced by its consumer base size and stability, demographic trends, and competitive positioning. Industries with volatile markets may see rapid changes in consumer preferences impacting stock price stability.
The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
Read more